Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-l...

by Rosell, Rafael, Dr, Carcereny, Enric, MD, Gervais, Radj, MD, Vergnenegre, Alain, Prof, Massuti, Bartomeu, MD, Felip, Enriqueta, MD, Palmero, Ramon, MD, Garcia-Gomez, Ramon, MD, Pallares, Cinta, MD, Sanchez, Jose Miguel, MD, Porta, Rut, MD, Cobo, Manuel, MD, Garrido, Pilar, MD, Longo, Flavia, MD, Moran, Teresa, MD, Insa, Amelia, MD, De Marinis, Filippo, MD, Corre, Romain, MD, Bover, Isabel, MD, Illiano, Alfonso, MD, Dansin, Eric, MD, de Castro, Javier, MD, Milella, Michele, MD, Reguart, Noemi, MD, Altavilla, Giuseppe, MD, Jimenez, Ulpiano, MD, Provencio, Mariano, MD, Moreno, Miguel Angel, MD, Terrasa, Josefa, MD, Muñoz-Langa, Jose, MD, Valdivia, Javier, MD, Isla, Dolores, MD, Domine, Manuel, MD, Molinier, Olivier, MD, Mazieres, Julien, Prof, Baize, Nathalie, MD, Garcia-Campelo, Rosario, MD, Robinet, Gilles, MD, Rodriguez-Abreu, Delvys, MD, Lopez-Vivanco, Guillermo, MD, Gebbia, Vittorio, MD, Ferrera-Delgado, Lioba, MD, Bombaron, Pierre, MD, Bernabe, Reyes, MD, Bearz, Alessandra, MD, Artal, Angel, MD, Cortesi, Enrico, MD, Rolfo, Christian, MD, Sanchez-Ronco, Maria, PhD, Drozdowskyj, Ana, PhD, Queralt, Cristina, PhD, de Aguirre, Itziar, PhD, Ramirez, Jose Luis, PhD, Sanchez, Jose Javier, Prof, Molina, Miguel Angel, PhD, Taron, Miquel, PhD, Paz-Ares, Luis, MD
Published in The lancet oncology

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled tri...

by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD
Published in The lancet oncology

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

by Kulukian, Anita, Lee, Patrice, Taylor, Janelle, Rosler, Robert, de Vries, Peter, Watson, Daniel, Forero-Torres, Andres, Peterson, Scott
Published in Molecular cancer therapeutics

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial

by Li, Jin, Qin, Shukui, Xu, Rui-Hua, Shen, Lin, Xu, Jianming, Bai, Yuxian, Yang, Lei, Deng, Yanhong, Chen, Zhen-dong, Zhong, Haijun, Pan, Hongming, Guo, Weijian, Shu, Yongqian, Yuan, Ying, Zhou, Jianfeng, Xu, Nong, Liu, Tianshu, Ma, Dong, Wu, Changping, Cheng, Ying, Chen, Donghui, Li, Wei, Sun, Sanyuan, Yu, Zhuang, Cao, Peiguo, Chen, Haihui, Wang, Jiejun, Wang, Shubin, Wang, Hongbing, Fan, Songhua, Hua, Ye, Su, Weiguo
Published in JAMA : the journal of the American Medical Association

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label,...

by Zhou, Caicun, Prof, Wu, Yi-Long, Prof, Chen, Gongyan, Prof, Feng, Jifeng, Prof, Liu, Xiao-Qing, Prof, Wang, Changli, Prof, Zhang, Shucai, Prof, Wang, Jie, Prof, Zhou, Songwen, MD, Ren, Shengxiang, MD, Lu, Shun, Prof, Zhang, Li, Prof, Hu, Chengping, Prof, Hu, Chunhong, Prof, Luo, Yi, Prof, Chen, Lei, Prof, Ye, Ming, Prof, Huang, Jianan, Prof, Zhi, Xiuyi, Prof, Zhang, Yiping, Prof, Xiu, Qingyu, Prof, Ma, Jun, Prof, You, Changxuan, Prof
Published in The lancet oncology

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

by Zhong, Wen-Zhao, Wang, Qun, Mao, Wei-Min, Xu, Song-Tao, Wu, Lin, Shen, Yi, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Xu, Lin, Wang, Jun, Fei, Ke, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Yan, Hong-Hong, Yang, Xue-Ning, Zhou, Qing, Wu, Yi-Long, Wu, Yi-Long, Wang, Qun, Mao, Wei-Min, Wu, Lin, Shen, Yi, Liu, Yong-Yu, Chen, Chun, Cheng, Ying, Xu, Lin, Wang, Jun, Fei, Ke, Li, Xiao-Fei, Li, Jian, Huang, Cheng, Liu, Zhi-Dong, Xu, Shun, Chen, Ke-Neng, Xu, Shi-Dong, Liu, Lun-Xu, Yu, Ping, Wang, Bu-Hai, Ma, Hai-Tao, Wang, Si-Yu, Hu, Jian, Liu, Wei, Li, Wei, Shi, Jian-Hua
Published in The lancet oncology

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall...

by Diéras, Véronique, Dr, Miles, David, Prof, Verma, Sunil, MD, Pegram, Mark, Prof, Welslau, Manfred, MD, Baselga, José, MD, Krop, Ian E, MD, Blackwell, Kim, Prof, Hoersch, Silke, MSc, Xu, Jin, PhD, Green, Marjorie, MD, Gianni, Luca, MD
Published in The lancet oncology

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin...

by Patnaik, A., Appleman, L.J., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Weiss, G.J., Sachdev, J.C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J.M., Lotze, M.T., Toledo, F.G.S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R.K.
Published in Annals of oncology

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3...

by Matasar, Matthew J, Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yañez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Baker, Ross, Bondarenko, Igor, Zhang, Qingyuan, Feng, Jifeng, Geissler, Klaus, Lazaroiu, Mihaela, Saydam, Guray, Szomor, Árpád, Bouabdallah, Krimo, Galiulin, Rinat, Uchida, Toshiki, Soler, Lidia Mongay, Cao, Anjun, Hiemeyer, Florian, Mehra, Aruna, Childs, Barrett H, Shi, Yuankai, Zinzani, Pier Luigi
Published in The lancet oncology

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

by Baselga, José, Dr, Bradbury, Ian, PhD, Eidtmann, Holger, MD, Di Cosimo, Serena, MD, de Azambuja, Evandro, MD, Aura, Claudia, MD, Gómez, Henry, MD, Dinh, Phuong, MD, Fauria, Karine, PhD, Van Dooren, Veerle, MSc, Aktan, Gursel, MD, Goldhirsch, Aron, MD, Chang, Tsai-Wang, MD, Horváth, Zsolt, MD, Coccia-Portugal, Maria, MD, Domont, Julien, MD, Tseng, Ling-Min, MD, Kunz, Georg, MD, Sohn, Joo Hyuk, MD, Semiglazov, Vladimir, MD, Lerzo, Guillermo, MD, Palacova, Marketa, MD, Probachai, Volodymyr, MD, Pusztai, Lajos, DPhil, Untch, Michael, PhD, Gelber, Richard D, PhD, Piccart-Gebhart, Martine, PhD
Published in The Lancet (British edition)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

by Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C, Jiang, B Y, Bai, X Y, Zhong, W Z, Yang, X N, Wu, Y L
Published in British journal of cancer

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

by Kim, Richard D, Sarker, Debashis, Meyer, Tim, Yau, Thomas, Macarulla, Teresa, Park, Joong-Won, Choo, Su Pin, Hollebecque, Antoine, Sung, Max W, Lim, Ho-Yeong, Mazzaferro, Vincenzo, Trojan, Joerg, Zhu, Andrew X, Yoon, Jung-Hwan, Sharma, Sunil, Lin, Zhong-Zhe, Chan, Stephen L, Faivre, Sandrine, Feun, Lynn G, Yen, Chia-Jui, Dufour, Jean-Francois, Palmer, Daniel H, Llovet, Josep M, Manoogian, Melissa, Tugnait, Meera, Stransky, Nicolas, Hagel, Margit, Kohl, Nancy E, Lengauer, Christoph, Sherwin, Cori Ann, Schmidt-Kittler, Oleg, Hoeflich, Klaus P, Shi, Hongliang, Wolf, Beni B, Kang, Yoon-Koo
Published in Cancer discovery

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

by Bachelot, Thomas, Dr, Romieu, Gilles, MD, Campone, Mario, MD, Diéras, Véronique, MD, Cropet, Claire, MSc, Dalenc, Florence, MD, Jimenez, Marta, MSc, Le Rhun, Emilie, MD, Pierga, Jean-Yves, MD, Gonçalves, Anthony, MD, Leheurteur, Marianne, MD, Domont, Julien, MD, Gutierrez, Maya, MD, Curé, Hervé, Prof, Ferrero, Jean-Marc, Prof, Labbe-Devilliers, Catherine, MD
Published in The lancet oncology

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

by Liu, Joyce F, Dr, Barry, William T, PhD, Birrer, Michael, MD, Lee, Jung-Min, MD, Buckanovich, Ronald J, MD, Fleming, Gini F, Prof, Rimel, BJ, MD, Buss, Mary K, MD, Nattam, Sreenivasa, MD, Hurteau, Jean, MD, Luo, Weixiu, MS, Quy, Philippa, MA, Whalen, Christin, BSN, Obermayer, Lisa, BA, Lee, Hang, PhD, Winer, Eric P, Prof, Kohn, Elise C, MD, Ivy, S Percy, MD, Matulonis, Ursula A, MD
Published in The lancet oncology

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

by Sundaresan, Tilak K, Sequist, Lecia V, Heymach, John V, Riely, Gregory J, Jänne, Pasi A, Koch, Walter H, Sullivan, James P, Fox, Douglas B, Maher, Robert, Muzikansky, Alona, Webb, Andrew, Tran, Hai T, Giri, Uma, Fleisher, Martin, Yu, Helena A, Wei, Wen, Johnson, Bruce E, Barber, Thomas A, Walsh, John R, Engelman, Jeffrey A, Stott, Shannon L, Kapur, Ravi, Maheswaran, Shyamala, Toner, Mehmet, Haber, Daniel A
Published in Clinical cancer research

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

by Ercan, Dalia, Choi, Hwan Geun, Yun, Cai-Hong, Capelletti, Marzia, Xie, Ting, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A
Published in Clinical cancer research

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

by Lee, Jeeyun, Prof, Park, Se Hoon, Prof, Chang, Heung-Moon, Prof, Kim, Jun Suk, Prof, Choi, Hye Jin, MD, Lee, Myung Ah, Prof, Chang, Joung Soon, Prof, Jeung, Hei Cheul, Prof, Kang, Jung Hun, Prof, Lee, Hyun Woo, Prof, Shin, Dong Bok, Prof, Kang, Hye Jin, MD, Sun, Jong-Mu, MD, Park, Joon Oh, Prof, Park, Young Suk, Prof, Kang, Won Ki, Prof, Lim, Ho Yeong, Prof
Published in The lancet oncology

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

by Robidoux, André, Prof, Tang, Gong, PhD, Rastogi, Priya, MD, Geyer, Charles E, Prof, Azar, Catherine A, MD, Atkins, James N, MD, Fehrenbacher, Louis, MD, Bear, Harry D, MD, Baez-Diaz, Louis, MD, Sarwar, Shakir, MD, Margolese, Richard G, MD, Farrar, William B, Prof, Brufsky, Adam M, Prof, Shibata, Henry R, Prof, Bandos, Hanna, PhD, Paik, Soonmyung, Prof, Costantino, Joseph P, Prof, Swain, Sandra M, Prof, Mamounas, Eleftherios P, Prof, Wolmark, Norman, Prof
Published in The lancet oncology

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept,...

by Sartore-Bianchi, Andrea, MD, Trusolino, Livio, MD, Martino, Cosimo, PhD, Bencardino, Katia, MD, Lonardi, Sara, MD, Bergamo, Francesca, MD, Zagonel, Vittorina, MD, Leone, Francesco, MD, Depetris, Ilaria, MD, Martinelli, Erika, MD, Troiani, Teresa, MD, Ciardiello, Fortunato, Prof, Racca, Patrizia, MD, Bertotti, Andrea, MD, Siravegna, Giulia, MSc, Torri, Valter, MD, Amatu, Alessio, MD, Ghezzi, Silvia, MSc, Marrapese, Giovanna, PhD, Palmeri, Laura, MD, Valtorta, Emanuele, PhD, Cassingena, Andrea, MSc, Lauricella, Calogero, PhD, Vanzulli, Angelo, MD, Regge, Daniele, MD, Veronese, Silvio, MSc, Comoglio, Paolo M, Prof, Bardelli, Alberto, PhD, Marsoni, Silvia, Dr, Siena, Salvatore, Prof
Published in The lancet oncology

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results fr...

by Krop, Ian E, Dr, Kim, Sung-Bae, Prof, Martin, Antonio Gonzalez, MD, LoRusso, Patricia M, Prof, Ferrero, Jean-Marc, MD, Badovinac-Crnjevic, Tanja, MD, Hoersch, Silke, MSc, Smitt, Melanie, MD, Wildiers, Hans, Prof
Published in The lancet oncology